The group is attacking PBMs and “short-sighted policies that would disrupt the development of the cures and medicines that patients depend on.” (Photo: Shutterstock)
A “shadowy” drug pricing advocacy organization that made its first appearance this week has proved to be backed by a Republican lobbying firm.
According to Stat News, the Alliance to Protect Medical Innovation announced its goal was to “help educate policymakers and the public about medical breakthroughs developed by the biopharmaceutical industry.” The report adds that the new group's “About Us” section on its website describes it as a 501(c)(4) nonprofit.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Marlene Satter
Marlene Y. Satter has worked in and written about the financial industry for decades.
